Literature DB >> 26454647

Precancerous histopathologic lesions of upper gastrointestinal tract among dyspeptic patients upon endoscopic evaluations.

Ghobad Abangah1, Asghar Rahmani2, Mohammad Reza Hafezi-Ahmadi3, Tayebeh Emami2, Khairollah Asadollahi4, Ali Jaafari-Haidarlo1, Atefeh Moradkhani2.   

Abstract

PURPOSE: Gastric cancer is one of the most important causes of morbidity and mortality worldwide which is influenced by different risk factors. This study aimed to investigate the effects of various factors associated with precancerous lesions among dyspeptic patients.
METHODS: Among dyspeptic patients admitted to gastrointestinal clinics in Ilam city, west of Iran, 1123 were investigated during 2008 to 2011. All patients were evaluated by endoscopy and their biopsy samples were examined for histological differentiations and their pathology reports were classified according to Sydney criteria.
RESULTS: One thousand out of 1123 admitted dyspeptic patients were finally analyzed. The mean age of participants was 48 years (ranged 21-84 years), and 64.8% of patients were male. The frequency of patients with atrophy, metaplasia, or both was 14.4%, adenocarcinoma 1.2%, and polyp hyperplasia 0.7%, respectively. The highest frequency was related to those with chronic gastritis accompanied by Helicobacter pylori infection with a figure of 80.8%. The frequency of precancerous lesions among smokers compared to non-smokers was higher significantly (p < 0.03). Though non-significant, BMI was associated with the higher risk of premalignant lesions among dyspeptic patients by an increasing manner.
CONCLUSION: Chronic gastritis accompanied with H. pylori infection was revealed as the most prevalent variable among dyspeptic patients. Also, higher BMI compared to normal and smokers compared to non-smokers were more involved by precancerous lesions.

Entities:  

Keywords:  Dyspeptic patients; Histopathologic lesions; Precancerous; Upper gastrointestinal tract

Mesh:

Year:  2016        PMID: 26454647     DOI: 10.1007/s12029-015-9760-x

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  26 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

Review 2.  Review article: exploring the link between Helicobacter pylori and gastric cancer.

Authors:  E J Kuipers
Journal:  Aliment Pharmacol Ther       Date:  1999-03       Impact factor: 8.171

3.  Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese.

Authors:  Taiji Matsuo; Masanori Ito; Shunsuke Takata; Shinji Tanaka; Masaharu Yoshihara; Kazuaki Chayama
Journal:  Helicobacter       Date:  2011-12       Impact factor: 5.753

4.  Evaluation of a mass screening program for stomach cancer with a case-control study design.

Authors:  A Oshima; N Hirata; T Ubukata; K Umeda; I Fujimoto
Journal:  Int J Cancer       Date:  1986-12-15       Impact factor: 7.396

5.  The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer.

Authors:  C M den Hoed; B C van Eijck; L G Capelle; H van Dekken; K Biermann; P D Siersema; E J Kuipers
Journal:  Eur J Cancer       Date:  2011-01-14       Impact factor: 9.162

6.  The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study.

Authors:  A Fukao; Y Tsubono; I Tsuji; S HIsamichi; N Sugahara; A Takano
Journal:  Int J Cancer       Date:  1995-01-03       Impact factor: 7.396

7.  Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis.

Authors:  Shigeto Mizuno; Ikuya Miki; Tsukasa Ishida; Masaru Yoshida; Mitsuko Onoyama; Takeshi Azuma; Yasuki Habu; Hideto Inokuchi; Kotaro Ozasa; Kazumasa Miki; Yoshiyuki Watanabe
Journal:  Dig Dis Sci       Date:  2010-03-04       Impact factor: 3.199

8.  The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis.

Authors:  S A Hundahl; J L Phillips; H R Menck
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

9.  Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG).

Authors:  George Papaxoinis; Sotirios Papageorgiou; Dimitra Rontogianni; Vassiliki Kaloutsi; George Fountzilas; Nikolaos Pavlidis; Meletios Dimopoulos; Constantinos Tsatalas; Nikolaos Xiros; Theofanis Economopoulos
Journal:  Leuk Lymphoma       Date:  2006-10

10.  Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma.

Authors:  J Parsonnet; I M Samloff; L M Nelson; N Orentreich; J H Vogelman; G D Friedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 Sep-Oct       Impact factor: 4.254

View more
  4 in total

1.  Prevalence of Gastric Preneoplastic Lesions in First-Degree Relatives of Patients with Gastric Cancer: a Cross-Sectional Study.

Authors:  Sergio Sotelo; Carlos Manterola; Tamara Otzen; Erik Morales; Iván Castillo
Journal:  J Gastrointest Cancer       Date:  2022-04-30

2.  Correlation between TAP detection and common digestive tract precancerous lesions.

Authors:  Changqing Sun; Fang Deng; Lingjun Meng; Guohua Chen
Journal:  Oncol Lett       Date:  2017-11-28       Impact factor: 2.967

3.  AGA Technical Review on Gastric Intestinal Metaplasia-Epidemiology and Risk Factors.

Authors:  Osama Altayar; Perica Davitkov; Shailja C Shah; Andrew J Gawron; Douglas R Morgan; Kevin Turner; Reem A Mustafa
Journal:  Gastroenterology       Date:  2019-12-06       Impact factor: 22.682

4.  Advancing the Science in Gastric Pre-Neoplasia: Study Design Considerations.

Authors:  Perica Davitkov; Osama Altayar; Shailja C Shah; Andrew J Gawron; Reem A Mustafa; Shahnaz Sultan; Douglas R Morgan
Journal:  Gastroenterology       Date:  2019-12-06       Impact factor: 22.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.